Cartesian Therapeutics Inc (NAS:RNAC)
$ 18.83 0.92 (5.14%) Market Cap: 478.56 Mil Enterprise Value: 274.02 Mil PE Ratio: 0 PB Ratio: 607.42 GF Score: 52/100

Q3 2022 Selecta Biosciences Inc Earnings Call Transcript

Nov 03, 2022 / 12:30PM GMT
Release Date Price: $50.7 (+3.68%)
Operator

Good morning, and welcome to the Selecta Biosciences Third Quarter 2022 Financial Results and Business Update Conference Call. (Operator Instructions) This call is being webcast live on the Investor and Media section of Selecta's website at www.selectabio.com and is being recorded. (Operator Instructions)

For opening remarks, I would like to introduce you, Mr. Kevin Tan, Chief Financial Officer of Selecta. Please go ahead, sir.

Kevin Tan
Selecta Biosciences, Inc. - CFO

Thank you, and good morning. Welcome to our third quarter 2022 financial results and business update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website, worldwide web selectabio.com, and our quarterly report on Form 10-Q for the quarter ended September 30, 2022, which we intend to file in the coming days with the Securities and Exchange Commission, or SEC.

Joining me today are Carsten Brunn, President and Chief Executive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot